REPRIEVE - A Randomized Trial to Prevent Vascular Events in HIV

Population: Age 40-75 on ART not receiving a statin
Brief Description: Double-blind, randomized, placebo-controlled, multicenter efficacy study in 6500 subjects. Primary objective is to determine if pitavastatin prevents major CVD events in HIV
Eligibility: On ART, age 40-75, CD4 >100, calculated 10-yr CVD risk <10%, LDL <190, no prior stroke/MI/PVD or diabetes, no use of lipid lowering drugs
Duration: Up to 72 months with study visits every 4 months. Compensation provided.
Nurse(s): Bartolo Santos, RN  323-343-8278
Connie Funk, RN  323-343-8282
Study Website:




Version en Espanol | English Version

2003 - 2009 AIDS Clinical Trials Unit, Keck School of Medicine of USC. All rights reserved.